Lataa...
GD2 and GD3 synthase: novel drug targets for cancer therapy
Our recent study suggests that targeting GD3 synthase (also known as ST8SIA1)—the rate-limiting enzyme in biosynthesis of the breast cancer stem cell marker GD2—abrogates metastasis and depletes the cancer stem cell populations within a tumor, thus providing an effective therapeutic strategy against...
Tallennettuna:
| Julkaisussa: | Mol Cell Oncol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4905286/ https://ncbi.nlm.nih.gov/pubmed/27308452 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/23723556.2014.975068 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|